Product Name :
Ppc-1
Description:
Ppc-1 is a mitochondrial uncoupler. Ppc-1 enhances mitochondrial oxygen consumption without adverse effects on ATP production. Ppc-1 is a cell-permeate interleukin-2 (IL-2) inhibitor. Ppc-1 inhibits the Gram-negative periodontopathogen Porphyromonas gingivalis. Ppc-1 has anti-obesity, antibacterial and anti-inflammatory activities.
CAS:
1245818-17-0
Molecular Weight:
355.43
Formula:
C21H25NO4
Chemical Name:
3-methylbut-2-en-1-yl 4-methoxy-8-[(3-methylbut-2-en-1-yl)oxy]quinoline-2-carboxylate
Smiles :
COC1=CC(=NC2C1=CC=CC=2OCC=C(C)C)C(=O)OCC=C(C)C
InChiKey:
PBLQSFOIWOTFNY-UHFFFAOYSA-N
InChi :
InChI=1S/C21H25NO4/c1-14(2)9-11-25-18-8-6-7-16-19(24-5)13-17(22-20(16)18)21(23)26-12-10-15(3)4/h6-10,13H,11-12H2,1-5H3
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.{{Brentuximab vedotin (solution)} web|{Brentuximab vedotin (solution)} Apoptosis|{Brentuximab vedotin (solution)} Purity & Documentation|{Brentuximab vedotin (solution)} Description|{Brentuximab vedotin (solution)} manufacturer|{Brentuximab vedotin (solution)} Epigenetics}
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
Ppc-1 is a mitochondrial uncoupler. Ppc-1 enhances mitochondrial oxygen consumption without adverse effects on ATP production. Ppc-1 is a cell-permeate interleukin-2 (IL-2) inhibitor. Ppc-1 inhibits the Gram-negative periodontopathogen Porphyromonas gingivalis. Ppc-1 has anti-obesity, antibacterial and anti-inflammatory activities.|Product information|CAS Number: 1245818-17-0|Molecular Weight: 355.43|Formula: C21H25NO4|Chemical Name: 3-methylbut-2-en-1-yl 4-methoxy-8-[(3-methylbut-2-en-1-yl)oxy]quinoline-2-carboxylate|Smiles: COC1=CC(=NC2C1=CC=CC=2OCC=C(C)C)C(=O)OCC=C(C)C|InChiKey: PBLQSFOIWOTFNY-UHFFFAOYSA-N|InChi: InChI=1S/C21H25NO4/c1-14(2)9-11-25-18-8-6-7-16-19(24-5)13-17(22-20(16)18)21(23)26-12-10-15(3)4/h6-10,13H,11-12H2,1-5H3|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.{{Galcuronokinase} site|{Galcuronokinase} Apoptosis|{Galcuronokinase} Purity & Documentation|{Galcuronokinase} In Vitro|{Galcuronokinase} manufacturer|{Galcuronokinase} Epigenetic Reader Domain} |Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.PMID:23937941 |Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|Ppc-1 treatment (0-10 μM; 24 hours; Jurkat cells) significant inhibits IL-2 production in Jurkat cells with an IC50 of 4 μM. Ppc-1 (compound 6) has antiproliferative activities in K562 human leukemia, Hela cervical carcinoma, and 3T3-L1 mouse embryonic fibroblast cells. Ppc-1 shows about 50% inhibition at 15 μM in all cell lines. Ppc-1 inhibits the growth of K562 cells with an EC50 of 13 μM.Using the U937-3xκB-LUC human monocytic cell line, Ppc-1 dose-dependently inhibits the lipopolysaccharide-induced NF-κB activation.|In Vivo:|Ppc-1 (0-10 mg /kg; Intraperitoneal injection; once a week; for 8 weeks; female ICR mice) treatment suppresses weight gain with no abnormal effects on liver or kidney tissues, and no evidence of tumor formation. Serum fatty acid levels are significantly elevated in mice treated with Ppc-1, while body fat content remained low. After a single administration, Ppc-1 distributes into various tissues of individual animals at low levels. Ppc-1 stimulates adipocytes in culture to release fatty acids, which might explain the elevated serum fatty acids in Ppc-1-treated mice.|Products are for research use only. Not for human use.|
